Cefditoren pivoxil
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-00719 |
| CAS | 117467-28-4 |
| Molecular Weight | 620.72 |
| Molecular Formula | C25H28N6O7S3 |
| Purity | ≥ 98% |
Online Inquiry
Description
It is produced by the strain of Semisynthetic third generation oral cephalosporin. Cefditoren Pivoxil possesses a broad-spectrum of antibacterial activity against both Gram-positive and Gram-negative species with stability to many beta-lactamases of clinical importance.
Specification
| Related CAS | 1448435-17-3 (hydrochloride) |
| Synonyms | Spectracef; Cefditoren pivaloyloxymethyl ester; CDTR-PI; Cefditorin; Meiact; Cefditoren PI voxil; (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-((Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido)-3-((Z)-2-(4-methylthiazol-5-yl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; ME-1207; ME 1207; ME1207 |
| Storage | −20 °C |
| IUPAC Name | 2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Canonical SMILES | CC1=C(SC=N1)C=CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C |
| InChI | InChI=1S/C25H28N6O7S3/c1-12-15(41-10-27-12)7-6-13-8-39-21-17(29-19(32)16(30-36-5)14-9-40-24(26)28-14)20(33)31(21)18(13)22(34)37-11-38-23(35)25(2,3)4/h6-7,9-10,17,21H,8,11H2,1-5H3,(H2,26,28)(H,29,32)/b7-6+,30-16+/t17-,21-/m1/s1 |
| InChI Key | AFZFFLVORLEPPO-BFQXLQLQSA-N |
Properties
| Appearance | Off-White to Pale Yellow Solid |
| Application | Anti-Bacterial Agents |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria |
| Melting Point | > 200 °C (dec.) |
| Density | 1.55±0.1 g/cm3 (Predicted) |
| Solubility | Slightly soluble in DMSO, Ethanol, Methanol (Heated) |
Reference Reading
1.Application of silver nanoparticles to the chemiluminescence determination of cefditoren pivoxil using the luminol-ferricyanide system.
Alarfaj NA1, Aly FA, El-Tohamy MF. Luminescence. 2015 Feb;30(1):91-7. doi: 10.1002/bio.2696. Epub 2014 May 22.
A new simple, accurate and sensitive sequential injection analysis chemiluminescence (CL) detection method for the determination of cefditoren pivoxil (CTP) has been developed. The developed method was based on the enhancement effect of silver nanoparticles on the CL signal arising from a luminol-potassium ferricyanide reaction in the presence of CTP. The optimum conditions relevant to the effect of luminol, potassium ferricyanide and silver nanoparticle concentrations were investigated. The proposed method showed linear relationships between relative CL intensity and the investigated drug concentration at the range 0.001-5000 ng/mL, (r = 0.9998, n = 12) with a detection limit of 0.5 pg/mL and quantification limit of 0.001 ng/mL. The relative standard deviation was 1.6%. The proposed method was employed for the determination of CTP in bulk drug, in its pharmaceutical dosage forms and biological fluids such as human serum and urine. The interference of some common additive compounds such as glucose, lactose, starch, talc and magnesium stearate was investigated.
2.Population data analysis of dissolution time profiles: Assessment of physicochemical properties of the drug, drug particles and the pharmaceutical formulation.
Horkovics-Kovats S1, Brunovský P2, Pichler A3, Bulitta JB4. Eur J Pharm Sci. 2015 Oct 12;78:245-54. doi: 10.1016/j.ejps.2015.07.017. Epub 2015 Jul 26.
Disintegration of finished dosage forms (FDF) and drug dissolution are fundamentally important processes that affect bioavailability. Established theories do not account for disintegration and usually assume sink conditions for drug dissolution that often do not apply. We present the theory to describe the disintegration of FDF with subsequent dissolution of liberated particles containing the active pharmaceutical ingredient (API) and its application using population data analysis. Population modeling, using dissolution profiles of 400mg cefditoren pivoxil tablets manufactured under various tableting pressures, characterized the intrinsic lifetime distribution of the particles and identified the presence of crystalline API in the formulation that was proven by X-ray diffraction. Modeling further estimated the disintegration time of FDF, the solubility of the amorphous API and its chemical instability in the medium that were in agreement with the experimentally determined values.
3.Preparation and characterization of cefditoren pivoxil-loaded liposomes for controlled in vitro and in vivo drug release.
Venugopalarao G1, Lakshmipathy R2, Sarada NC1. Int J Nanomedicine. 2015 Oct 1;10 Suppl 1:149-57. doi: 10.2147/IJN.S79994. eCollection 2015.
BACKGROUND: The application of antibiotics has been limited due to weak biodistribution and pharmacokinetics. Encapsulation of these drugs in lipid vesicles might be a good solution for obtaining the required properties. Liposomes are one of the most suitable drug-delivery systems to deliver the drug to the target organ and minimize the distribution of the drug to non-target tissues.
4.A Comparison of Cefditoren Pivoxil 8-12 mg/kg/day and Cefditoren Pivoxil 16-20 mg/kg/day in Treatment of Children With Acute Presumed Bacteri
Poachanukoon O1, Tangsathapornpong A2, Tanuchit S3. Clin Exp Otorhinolaryngol. 2015 Jun;8(2):129-35. doi: 10.3342/ceo.2015.8.2.129. Epub 2015 May 13.
OBJECTIVES: Cefditoren pivoxil (CDT) has been used in the treatment of rhinosinusitis. However, little is known about the efficacy of this drug at low and high doses. This study was to compare the efficacy and safety of low dose (8-12 mg/kg/day) and high dose (16-20 mg/kg/day) CDT in the treatment of children with uncomplicated acute rhinosinusitis (ARS).
Recommended Products
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
